Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The change is a revision update from v3.4.1 to v3.4.2 with no impact on study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-15T15:02:27.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Peking University People's Hospital was added as a study site in early 2026 after a prior removal in December 2025; the page revision also updated from v3.4.0 to v3.4.1.
    Difference
    0.1%
    Check dated 2026-02-08T11:25:47.000Z thumbnail image
  4. Check
    31 days ago
    Change Detected
    Summary
    Adds a glossary toggle and makes small text/capitalization changes to metadata fields (e.g., Last Update statuses and No FEAR Act data). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-25T03:46:12.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Revision tag updated from v3.3.3 to v3.3.4; no changes to the study details or page content were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-18T01:53:34.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    Two new study sites were added: Chongqing, China (400042) and Thane, India (411107). The list also shows removal/rename of Yuzhong District (Chongqing 400042) and Thāne (411107).
    Difference
    0.1%
    Check dated 2025-12-27T18:25:44.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    - Locations section updated with an expanded list of US states and Canadian provinces. - Page revision updated to v3.3.3; HHS Vulnerability Disclosure section removed.
    Difference
    0.7%
    Check dated 2025-12-19T13:00:38.000Z thumbnail image

Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.